ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress, being held June 14-17, 2018 in Stockholm, Sweden.
The preclinical eryaspase data will be presented during Poster Session I by Dr. Karine Aguera, ERYTECH's R&D Project Leader.
|Poster Session: Preclinical Demonstration of Intracellular Activity of Asparaginase Encapsulated in Red Blood Cells Both in the Absence and in the Presence of Neutralizing Anti-Asparaginase Antibodies|
|Lead Author:||Karine Aguera|
|Poster Session:||Poster Session I|
|Date:||Friday, June 15, 2018|
|Time:||5:30 p.m. - 7:00 p.m. (CEST)|
|In these in vivo and in vitro preclinical studies, eryaspase was effective in reducing L-asparagine (ASN) levels, both in the presence and absence of neutralizing anti-asparaginase antibodies (nAbs). The preclinical findings, confirmed in additional in vitro experiments with eryaspase, support the theory that intra-cellular asparaginase activity may be responsible for the sustained effect on ASN reduction and can provide a more effective approach for the delivery of the L-asparaginase enzyme in patients with ALL, particularly in patients who have developed nAbs.|
|The AML Phase 2b trial data will be presented during Poster Session II by Dr. Mathilde Hunault of Centre Hospitalier Universitaire (CHU) d'Angers, France.|
|Poster Session: A Phase 2b of Eryaspase in Combination with Low-Dose Cytarabine as First-Line Therapy in Elderly Patients with Acute Myeloid Leukemia (ENFORCE - NCT01810705)|
|Lead Author:||Xavier Thomas|
|Poster Session:||Poster Session II|
|Date:||Saturday, June 16, 2018|
|Time:||5:30 p.m. - 7:00 p.m. (CEST)|
The Phase 2b trial to evaluate the efficacy of eryaspase in elderly AML patients did not meet its primary endpoint to improve overall survival in this difficult-to-treat patient population. Patient selection is likely the most important factor, with enrolled patients remaining only briefly on treatment and unable to achieve a potential drug effect. Individualized risk stratification based on multi-parameter assessment tools and co-morbidity burden should be considered for older adults with AML participating in clinical trials.
ERYTECH also has an abstract on the incidence of Venous Thromboembolism (VTE) in 125 ALL patients, treated in five studies.
Abstract: Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Eryaspase (L-Asparaginase Encapsulated in Red Blood Cells)
|Lead Author:||Yves Bertrand|
|Location:||EHA Website Abstracts|
The findings of this study show that the risk of VTE with eryaspase treatment in ALL patients was low and observed primarily in adults. The low incidence of these events may be related to decreased incidence of impaired coagulation parameters.
About ERYTECH: www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH's initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
The Company's lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.
Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing erymethionase, methionine-Y-lyase encapsulated in red blood cells, to target cancer cells' amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Director Investor Relations
|+33 4 78 74 44 38
+1 917 312 5151
|+33 1 44 71 98 52
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the potential of ERYTECH's product pipeline, its clinical development and regulatory plans for eryaspase, the timing of ERYTECH's clinical studies and trials and announcements of data from those studies and trials, and the contents and timing of decisions by the FDA and EMA regarding ERYTECH's product candidates. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company's Securities and Exchange Commission (SEC) filings and reports, including in the Company's 2017 Document de Référence filed with the AMF in April 2018 and in the Company's Annual Report on Form 20-F filed with the SEC on April 24, 2018, as amended on May 23, 2018, and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Erytech Pharma S.A. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Hexagon Mobile Pipeline® to virtually connect communities and industries to pipeline gas in the US6.6.2020 10:15:39 CEST | Press release
Hexagon Mobile Pipeline®, a Hexagon Composites subsidiary, has received a substantial contract for TITAN® 53 transport modules from Xpress Natural Gas LLC (XNG) a leading full-service provider of compressed natural gas (CNG). The strategic agreement has a total value of USD 7.3 million (approx. NOK 70.2 million) and includes additional purchase and rental options through 2021. The TITAN® 53 large-capacity Mobile Pipeline® modules will serve virtual interconnect projects providing natural gas to communities and industries that do not have access to sufficient pipeline capacity in the US. "Since XNG started operations in early 2013, Hexagon's Titan products have proven to be high-quality products that deliver safety, reliability and performance," says John Nahill, CEO and co-founder of Xpress Natural Gas. "The higher volume of TITAN®53 means that we can serve our customers with fewer trailers and miles driven and that is key to our success. We appreciate the expertise and responsiveness
NEW ANALYSES OF PHASE 2 EQUATOR CLINICAL PROGRAM SUPPORT DURABLE EFFICACY OF FILGOTINIB IN PSORIATIC ARTHRITIS5.6.2020 22:01:00 CEST | Press release
-- Data Were Presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology 2020 -- Foster City, Calif., & Mechelen, Belgium, 5 June 2020, 22.01 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with psoriatic arthritis (PsA). The data from the double-blind, placebo-controlled, Phase 2 EQUATOR study and the EQUATOR-2 open-label extension study demonstrate filgotinib’s durable efficacy and consistent safety profile in people with active PsA, and showed rapid and sustained reductions in inflammatory biomarkers in patients with moderate to severe PsA. The new analyses were presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology 2020. “Despite existing treatments, people living with psoriatic arthritis can face challenging long-term symptoms incl
Agility receives order from new major global logistics customer for CNG trucks5.6.2020 20:19:33 CEST | Press release
Agility Fuel Solutions, a business of Hexagon Composites, has signed a master services agreement with a global logistics customer to deliver compressed natural gas (CNG) fuel systems for medium and heavy-duty trucks. The initial order represents an estimated total value of USD 2.2 million (approx. NOK 20.5 million) with additional orders expected to follow. As a low carbon fuel, CNG can result in reductions of greenhouse gas (GHG) emissions compared to diesel of over 20% when using conventional natural gas, or 90% or more when using renewable natural gas (RNG) produced from landfills, dairy farms and other bio sources. “It makes environmental and economic sense to deploy CNG trucks right now, and the low cost and maturity of the technology make it possible to do so at scale,” says Seung Baik, President, Agility Fuel Solutions. Deliveries of the first order of CNG fuel systems are scheduled to start in the second quarter of 2020. For more information: David Bandele, CFO, Hexagon Composi
Hexagon Composites ASA: Mandatory Notification of Trade5.6.2020 17:11:41 CEST | Press release
Dan Krick, SVP Organizational Development has sold 24,896 shares in Hexagon Composites ASA at a price of NOK 36,42 per share. The sale is primarily to finance tax obligations from his exercise of options earlier in the year. After the transaction Dan Krick holds zero shares in Hexagon Composites ASA. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. For more information: David Bandele, CFO, Hexagon Composites ASA Telephone: +47 920 91 483 | email@example.com About Hexagon Composites Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation and conversion to clean energy in a wide range of mobility, industrial and consumer applications.
CONDITIONS FOR RIKSBANK BID PROCEDURES SEK GOVERNMENT BONDS5.6.2020 15:05:00 CEST | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2020-06-12 Maturity dateLoanISIN codeCouponVolume, SEK million2026-11-121059 SE00071259271.00 %1,000 +/- 2502031-05-12 1062 SE00139353190.125 %1,000 +/- 250 Settlement date 2020-06-16 Bids have to be entered by 10.00 on JUN 12, 2020 Highest permitted bid volume: 1 000 SEK million in issue SGB 1059 and 1 000 SEK million in issue SGB 1062 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON JUN 12, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved athttp://www.riksbank.se
Correction: Correction: Correction: AB Klaipedos nafta financial information reporting dates in 20205.6.2020 15:05:00 CEST | Press release
Correction: AB Klaipedos nafta social responsibility report for the year 2019 will be released on 9 June 2020. AB Klaipedos nafta (further – KN) informs that it plans to release financial information in 2020 according to the following schedule: DateReporting informationWithin first 5 working days of every month of 2020KN preliminary revenues* for the previous month31 January 2020Interim financial information for the year 20196 April 2020Audited financial statements for the year 201929 April 2020Interim financial information for the 1st quarter of 20209 June 2020Social responsibility report for the year 201931 July 2020Interim financial information for the 6 month of 202030 October 2020Interim financial information for the 3 quarters of 2020 On 28 April 2020, the Company plans to convene an Ordinary General Meeting of Shareholders. * It should be noted that from 2020 the company will be adjusting course of releasing monthly financial information. As range of the services provided to the